In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.
Combinations of caspofungin and posaconazole were evaluated by fractional inhibitory concentration index against 119 Candida glabrata isolates. Synergy was seen in 18% of all isolates and in 4% of fluconazole-resistant isolates at 48 h without evidence of antagonism. This antifungal combination may have utility against this organism.
Oliveira
E R
ER
Department of General Dentistry, University of Texas Health Science Center at San Antonio, Mail Code 7914, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. oliveirae@uthscsa.edu
Fothergill
A W
AW
Kirkpatrick
W R
WR
Coco
B J
BJ
Patterson
T F
TF
Redding
S W
SW
D000935:Antifungal Agents / Q000494:pharmacology*; D041221:Candida glabrata / Q000187:drug effects* / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000382:microbiology; D000077336:Caspofungin; D025141:Drug Resistance, Fungal; D004357:Drug Synergism; D054714:Echinocandins; D015725:Fluconazole / Q000494:pharmacology; D006801:Humans; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests / Q000379:methods; D010456:Peptides, Cyclic / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D014230:Triazoles; C101425:posaconazole; D015725:Fluconazole; D000077336:Caspofungin